One Of The Fusing Cells Is A Mouse Antibody-producing Cell Patents (Class 435/452)
-
Patent number: 6849720Abstract: There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.Type: GrantFiled: March 8, 2001Date of Patent: February 1, 2005Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nachum Yonah, Dany Suissa, Ilana Belzer, Francesco Antonetti, Moshe Smolarsky, Michel Dreano
-
Patent number: 6844164Abstract: An antibody biding specifically to rat's acrosome reacted sperm is produced and hybridomas (FARS-91 and FARS-92 strains) capable of stably proliferating are obtained by fusing mouse spleen cells having a high antibody titer against rat's acrosome reacted sperm with mouse-origin myeloma cells and screening fused cells reacting strongly with rat's acrosome reacted sperm. From these hybridomas, monoclonal antibodies selectively binding to rat's acrosome reacted sperm can be obtained. Thus, a diagnostic method for evaluating fertility of rat's spermatozoa is presented.Type: GrantFiled: October 23, 2000Date of Patent: January 18, 2005Assignee: FUSO Pharmaceutical Industries, Ltd.Inventors: Yoshihiro Kuwahara, Michinori Hasegawa, Kiyotsugu Isaka, Hiromasa Araki
-
Patent number: 6838250Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.Type: GrantFiled: March 29, 2001Date of Patent: January 4, 2005Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Edward R. Scalice, John L. Daiss
-
Patent number: 6719975Abstract: A method of making antibodies to hirudin by immunizing with an immunogenic composition containing polymerized hirudin monomers in the absence of carrier protein is taught.Type: GrantFiled: February 20, 1996Date of Patent: April 13, 2004Assignee: Farmitalia Carlo Erba S.r.l.Inventors: Antonio Molinari, Marco Gerna, Carla Giorgetti, Jacqueline Lansen, Romeo Roncucci
-
Patent number: 6716594Abstract: The invention relates to monoclonal antibody capable of specific binding to the molecular weight of 20 kDa variant of human growth hormone. This monoclonal antibody has no substantial binding to hGH of molecular weight 22 kDa. The invention also relates to the use of this monoclonal antibody for measurement of hGH 20K, especially in body fluids. The antibodies can be used for detection and quantification of hGH 20K, especially in serum.Type: GrantFiled: June 16, 1999Date of Patent: April 6, 2004Assignees: Pharmacia Spain SA, Consejo Superior de Investigaciones ScientificasInventors: Yngve Elof Hansson, Leonor Kremer Baron, Carlos Martínez Alonso, José Mario Mellado Garcia, José Miguel Rodriguez Frade
-
Patent number: 6709833Abstract: A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4-biphosphate (PI-3,4-P2) but does not cross-react with structurally similar phospholipid antigens is advantageous for PI-3,4-P2-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.Type: GrantFiled: March 3, 2000Date of Patent: March 23, 2004Assignees: Yasuhisa Fukui, Medical & Biological Laboratories, Co., Ltd.Inventors: Yasuhisa Fukui, Satoshi Nagata, Ryuichi Shirai, Naoaki Saito
-
Patent number: 6632620Abstract: The invention provides monoclonal antibodies that selectively bind to ectodermally- and endodermally-derived stem cells and methods for the diagnosis of a neoplasm in a subject by contacting a tissue sample from the subject with the antibodies. Also disclosed are methods for isolating such stem cells from a heterogeneous cell population by contacting the population with antibodies which selectively bind to stem cells.Type: GrantFiled: June 22, 2000Date of Patent: October 14, 2003Inventor: Andrew N. Makarovskiy
-
Patent number: 6630327Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.Type: GrantFiled: September 16, 1999Date of Patent: October 7, 2003Assignee: Board of Trustees of the University of IllinoisInventors: Eugene Mechetner, Igor B. Roninson
-
Patent number: 6613538Abstract: The present invention relates to the detection of HLA-G. Antibodies to both soluble and membrane bound HLA-G are disclosed. Exemplary antibodies include 2C/C8, 3C/G4, and 4H84. 2C/C8 and 4H84 antibodies bind to the same region of HLA-G, which is a different region than that bound by 3C/G4. Methods of detection and diagnosis are disclosed as well as kits, including a miniaturized assay suitable for a clinical setting. Further, a method of selecting an embryos for in vitro fertilization is disclosed. A sandwich ELISA test is provided using two antibodies that bind to HLA-G at different regions. The HLA-G test according to the invention is over 1000 times more selective in binding to HLA-G than to antigens HLA-A2, HLA-B4, HLA-C, or mixed WBC preparations.Type: GrantFiled: March 21, 2001Date of Patent: September 2, 2003Inventors: Clifford L. Librach, Shang-mian Yie
-
Patent number: 6593137Abstract: This invention provides a hybridoma produced by the fusion of a mouse antibody-producing cell and a mouse myeloma which is designated 1-10F-8A and deposited with the ATCC under Accession Number PTA-279, said hybridoma producing a monoclonal antibody which binds to fullerene C60. This invention provides a mouse monoclonal antibody specific for a fullerene-C60 and produced by the mouse monoclonal antibody-producing hybridoma designated 1-10F-8A. The invention provides the amino acid and encoding nucleic acid sequences of the heavy and light chains of the 1-10F-8A monoclonal antibody. This invention also provides methods of determining a serum concentration of a fullerene in a subject and of purifying a fullerene from a sample.Type: GrantFiled: August 31, 1999Date of Patent: July 15, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Bernard F. Erlanger, Bi-Xing Chen
-
Publication number: 20030087435Abstract: A system for the immune mediated in vivo hydrolysis of the nerve agent sarin, comprising metalloantibodies capable of hydrolyzing the nerve agent sarin, a cell culture method of raising these antibodies, an artificial antigen capable of stimulating the production of these antibodies, and a hapten analogue of sarin. A hapten analogue to sarin is formed by conjugating a Cr(III) trien with N&agr;, N&egr;-di(O,O-diisopropyl) phosphoryl L-lysine (DIP). This hapten is conjugated with key limpet hemocyanin (KLH) to form an antigen capable of eliciting antibodies with reactive sites for both metals and sarin. Antibodies formed in response to this antigen are cultured in an immortal cell line and purified. The steric proximity of binding sites on the antibody for the metal trien and sarin allows hydrolyzation of the F− moiety from sarin and sarin's resultant bioactive neutralization. Antibody hydrolysis activity is monitored by measurement of produced F−.Type: ApplicationFiled: July 8, 2002Publication date: May 8, 2003Inventor: Jeffrey J. Brandt
-
Publication number: 20030022291Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.Type: ApplicationFiled: May 24, 2002Publication date: January 30, 2003Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits
-
Patent number: 6387698Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.Type: GrantFiled: August 18, 2000Date of Patent: May 14, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
-
Patent number: 6358711Abstract: The invention provides a human testin (HTES) and polynucleotides which identify and encode HTES. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HTES.Type: GrantFiled: May 16, 2000Date of Patent: March 19, 2002Assignee: Incyte Genomics, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 6355485Abstract: A new and useful apparatus for producing cell electrofusion is provided. The apparatus comprises: a. a chamber with a substrate disposed therein, b. means for directing the cells to be fused toward one side of the substrate; and c. a device for inducing fusion of the portion of the cells.Type: GrantFiled: July 14, 2000Date of Patent: March 12, 2002Assignee: University of South FloridaInventors: Mark J. Jaroszeski, Richard A. Gilbert, Richard Heller
-
Patent number: 6348576Abstract: The invention provides a human cornichon protein (CORN) and polynucleotides which identify and encode CORN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of CORN.Type: GrantFiled: August 2, 1999Date of Patent: February 19, 2002Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 6322787Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.Type: GrantFiled: August 5, 1999Date of Patent: November 27, 2001Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Ralph Mocikat, Horst Lindhofer
-
Patent number: 6309880Abstract: A particular epitope located within the CD4-binding region of gpl20 of HIV-1, and antibodies specific for the epitope which can inhibit HIV-1 infection of human cells by diverse strains and isolates of the virus, is disclosed. The antibodies are useful for a number of purposes, including diagnosis of HIV-1 infection.Type: GrantFiled: July 9, 1993Date of Patent: October 30, 2001Assignee: Tanox, Inc.Inventors: Tse Wen Chang, Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun, Nancy T. Chang
-
Patent number: 6274334Abstract: A hybridoma cell line has been produced for secreting a monoclonal antibody that binds ractopamine and is effective to detect ractopamine levels of about 1 ng/mL or lower. This monoclonal antibody may be used for the detection and quantitative determination of trace amounts of ractopamine in samples, especially in animal tissue, body fluids and feed material.Type: GrantFiled: July 13, 2000Date of Patent: August 14, 2001Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Weilin L. Shelver, David J. Smith
-
Patent number: 6245897Abstract: A monoclonal antibody which recognizes lipopolysaccharide binding site of macrophage cell surface receptor CD14 and has binding activity to monocyte or macrophage cells. The monoclonal antibody suppresses the production of an inflammatory mediator such as TNF, IL-6 or NO at early stages by recognizing CD14, and competitively inhibiting its binding with LPS. Therefore, it is useful for pathology analysis and the treatment of sepsis.Type: GrantFiled: March 4, 1999Date of Patent: June 12, 2001Assignee: Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation)Inventors: Yoshiyuki Adachi, Naohito Ohno, Toshiro Yadomae
-
Patent number: 6210670Abstract: This invention provides monoclonal antibodies that bind to both E-selectin and to P-selectin, and inhibit the binding of these proteins to counterreceptors. The invention also provides nucleic acids encoding these antibodies and methods for using the antibodies in the treatment of inflammatory conditions.Type: GrantFiled: March 26, 1996Date of Patent: April 3, 2001Assignee: Protein Design Labs, Inc.Inventor: Ellen L. Berg
-
Patent number: 6197297Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18, 500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose.Type: GrantFiled: November 15, 1995Date of Patent: March 6, 2001Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
-
Patent number: 6159751Abstract: This invention provides a method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: (a) cotransfecting a CREF-Trans 6 cell line with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; (b) selecting transfected cells which express the selectable or identifiable trait; (c) recovering the cells so selected in step (b); (d) injecting the cells so recovered in step (c) into a suitable marine host; (e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the murine host; (f) isolating the tumor formed in step (e); (g) obtaining tumor cells from the isolated tumor in step (f); (h) coating the tumor cells obtained in step (9) with an antiserum generated against the CREF Trans-6 cell line (i) injecting the antiserum-coated cells from step (h) into a plurality of suitable secoType: GrantFiled: June 5, 1995Date of Patent: December 12, 2000Assignee: The Trustees of Columbia University in the City of New YorkInventor: Paul B. Fisher
-
Patent number: 6051228Abstract: The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.Type: GrantFiled: February 19, 1998Date of Patent: April 18, 2000Assignee: Bristol-Myers Squibb Co.Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath
-
Patent number: 6025165Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: GrantFiled: October 5, 1998Date of Patent: February 15, 2000Assignee: Enzon, Inc.Inventors: Marc D. Whitlow, James F. Wood, Karl D. Hardman, Robert E. Bird, David Filpula, Michele Rollence
-
Patent number: 6013519Abstract: The present invention relates to monoclonal antibodies (MAb) to hematopoietic facilitatory cells (FC). In particular, it relates to MAb against antigens expressed by murine FC, methods of generating the antibodies, and methods of using the same. MAb directed to markers that are expressed specifically or at higher levels by FC than by most other bone marrow cells have a wide range of applications, including but not limited to, rapid isolation of FC, identification of FC in a donor cell preparation, and molecular cloning of the genes encoding the corresponding target antigens.Type: GrantFiled: August 18, 1997Date of Patent: January 11, 2000Assignee: University of PittsburghInventors: Suzanne T. Ildstad, Christina Kaufman, Yolanda Colson
-
Patent number: 5985278Abstract: The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.Type: GrantFiled: December 19, 1995Date of Patent: November 16, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Francesc Mitjans, Jaume Piulats, Elisabet Rosell, Jaume Adan, Simon Goodman, Diane Hahn
-
Patent number: 5961974Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.Type: GrantFiled: May 24, 1994Date of Patent: October 5, 1999Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
-
Patent number: 5951983Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.Type: GrantFiled: June 7, 1995Date of Patent: September 14, 1999Assignees: Universite Catholique de Louvain, Bio Transplant, Inc.Inventors: Herve Bazin, Dominique Latinne, Ruth Kaplan, Thomas Kieber-Emmons, Christina E. Postema, Mary E. White-Scharf
-
Patent number: 5912176Abstract: This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV).Type: GrantFiled: June 2, 1997Date of Patent: June 15, 1999Assignee: United Biomedical, Inc.Inventor: Chang Yi Wang
-
Patent number: 5876716Abstract: A monoclonal or other antibody to the carbohydrate antigen Tn can be used to inhibit or slow the progression of AIDS or ARC. The antigen can be used in a vaccine, for immunisation.Type: GrantFiled: December 30, 1994Date of Patent: March 2, 1999Assignee: Bay Development Corporation SAInventors: John-Erik Stig Hansen, Henrik Clausen